| Literature DB >> 29495139 |
Hee Sung Kim1,2, Gilwon Kang1,3, Sunmi Lee4, Chang Gyo Yoon5, Minyoung Kim6.
Abstract
BACKGROUND: Chemoprophylaxis has been used to prevent malaria among soldiers and secondary transmission, as it effectively facilitates a decline in disease occurrence and secondary prevention. However, poor compliance and decreased risk of exposure to malaria necessitate that control strategies be reestablished.Entities:
Keywords: Chemoprophylaxis; Cost-Benefit Analysis; Malaria; Rapid Diagnostic Test Kit
Mesh:
Substances:
Year: 2018 PMID: 29495139 PMCID: PMC5832939 DOI: 10.3346/jkms.2018.33.e59
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Fig. 1Study framework.
Fig. 2Diagram of Plasmodium vivax transmission.
Sh = susceptible host, E1h = exposed host, E1sh = exposed host — short latent period in hepatic cycle, E1lh = exposed host — long latent period in hepatic cycle, E2h = exposed host — erythrocytic cycle, Ih = infectious host, Th = treated or recovered host, Sv = susceptible vector, Ev = exposed vector, Iv = infectious vector.
Fig. 3A mathematical model for Plasmodium vivax using a system of nonlinear ordinary differential equations.
Predicting the incidence of malaria in soldiers (veterans) during 2010–2012 according to chemoprophylaxis compliance and early diagnosis rate
| Strategies | 2010 | 2011 | 2012 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Chemoprophylaxis compliance | Early diagnosis | µ1 + µ2 + µ3 | µ1 + µ3 | No. of strategies | µ1 + µ2 + µ3 | µ1 + µ3 | No. of strategies | µ1 + µ2 + µ3 | µ1 + µ3 | No. of strategies |
| 50% | 50% | 402.6 (286.2) | 402.6 (286.2) | 2,582.6 (600.6) | 268.7 (177.9) | 268.7 (177.9) | 1,770.9 (388.6) | 99.0 (54.8) | 99.0 (54.8) | 565.9 (117.4) |
| 70% | 382.3 (275.9) | 382.3 (275.9) | 255.1 (171.6) | 255.1 (171.6) | 94.4 (53.1) | 94.4 (53.1) | ||||
| 100% | 355.4 (262.3) | 355.4 (262.3) | 237.3 (163.2) | 237.3 (163.2) | 88.3 (51.0) | 88.3 (51.0) | ||||
| 70% | 50% | 330.8 (233.9) | 330.8 (233.9) | 214.8 (141.6) | 214.8 (141.6) | 86.7 (47.9) | 86.7 (47.9) | |||
| 70% | 314.0 (225.5) | 314.0 (225.5) | 204.0 (136.5) | 204.0 (136.5) | 82.7 (46.5) | 82.7 (46.5) | ||||
| 100% | 292.0 (214.3) | 292.0 (214.3) | 189.7 (129.8) | 189.7 (129.8) | 77.3 (44.6) | 77.3 (44.6) | ||||
| 100% | 50% | 222.9 (155.6) | 223.0 (155.6) | 134.0 (87.1) | 134.0 (87.1) | 68.2 (37.5) | 68.2 (37.5) | |||
| 70% | 211.7 (149.8) | 211.7 (149.8) | 127.2 (83.9) | 127.2 (83.9) | 65.1 (36.4) | 65.1 (36.4) | ||||
| 100% | 196.8 (142.2) | 196.8 (142.2) | 118.3 (79.7) | 118.3 (79.7) | 60.9 (34.9) | 60.9 (34.9) | ||||
µ1 = use of chloroquine and primaquine during May and October, µ2 = use of primaquine during the first 2 weeks of October, µ3 = early diagnosis of malaria with a RDT kit within 5 days of fever.
RDT = rapid diagnostic test.
Details of benefit per reduction in malaria infection
| Care of malaria | 2010 | 2011 | 2012 | ||||
|---|---|---|---|---|---|---|---|
| Soldiers | Veterans | Soldiers | Veterans | Soldiers | Veterans | ||
| Outpatients | Medical cost | - | 60,964 | - | 77,712 | - | 70,004 |
| Transportation | - | 18,741 | - | 20,053 | - | 20,708 | |
| Productivity loss | - | 14,895 | - | 15,912 | - | 17,345 | |
| Inpatients | Medical cost | 711,877 | 653,450 | 724,691 | 803,065 | 731,098 | 921,485 |
| Transportation | 11,473 | 11,570 | 12,276 | 12,033 | 12,672 | 12,297 | |
| Caregivers | - | 406,277 | - | 443,250 | - | 492,941 | |
| Productivity loss | 613,692 | 194,980 | 645,993 | 210,850 | 679,986 | - | |
| Epidemiological investigation | 77,000 | - | 80,850 | - | 84,893 | - | |
| Total | 1,414,042 | 1,360,877 | 1,463,810 | 1,582,875 | 1,508,649 | 1,534,780 | |
Unit: KRW (average exchange rate in 2010 was 1 USD = 1,156.86 KRW).
Cost of each control measure by year
| Control measures | 2010 | 2011 | 2012 | Total |
|---|---|---|---|---|
| Chemoprophylaxis with CQ + PQ (μ1) | 4,929 | 4,616 | 3,295 | 12,840 |
| Chemoprophylaxis with PQ (µ2) | 1,999 | 1,875 | 1,339 | 5,213 |
| Early diagnosis (µ3), demand ① | 169 | 166 | 162 | 497 |
| Early diagnosis (µ3), demand ② | 30 | 30 | 30 | 90 |
| Early diagnosis (µ3), demand ③ | 162 | 162 | 162 | 486 |
Unit: one million KRW (average exchange rate in 2010 was 1 USD = 1,156.86 KRW). Estimated RDT kit demand based on suspected cases and tested cases using the RDT kit (Early diagnosis demand ①), estimating that the RDT kit demand will increase by 50% (Early diagnosis demand ②), estimating that 450 medical corps use RDT kits for febrile patients (Early diagnosis demand ③); the number is empirically estimated.
CQ = chloroquine, PQ = primaquine, µ1 = use of chloroquine and primaquine during May and October, µ2 = use of primaquine during the first 2 weeks of October, µ3 = early diagnosis of malaria with a RDT kit within 5 days of fever, RDT = rapid diagnostic test.
Benefit-cost ratio of chemoprophylaxis and early diagnosis by changing chemoprophylaxis compliance and the early diagnosis rate
| Chemoprophylaxis compliance | Early diagnosis | RDT demand | Strategy µ1 | Strategy µ1 + µ3 | Strategy µ3 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Benefit | Cost | B-C ratio | Benefit | Cost | B-C ratio | Benefit | Cost | B-C ratio | |||
| 50% | 50% | ① | 6,608,129,941 | 12,840,581,495 | 0.52 | 6,859,450,845 | 13,089,991,495 | 0.52 | 6,009,641,804 | 249,410,000 | 24.10 |
| ② | 6,608,129,941 | 12,840,581,495 | 0.52 | 6,859,450,845 | 13,290,581,495 | 0.52 | 6,009,641,804 | 450,000,000 | 13.35 | ||
| ③ | 6,608,129,941 | 12,840,581,495 | 0.52 | 6,859,450,845 | 15,270,581,495 | 0.45 | 6,009,641,804 | 2,430,000,000 | 2.47 | ||
| 70% | ① | 6,608,129,941 | 12,840,581,495 | 0.52 | 6,939,531,298 | 13,189,755,495 | 0.53 | 6,128,753,881 | 349,174,000 | 17.55 | |
| ② | 6,608,129,941 | 12,840,581,495 | 0.52 | 6,939,531,298 | 13,470,581,495 | 0.52 | 6,128,753,881 | 630,000,000 | 9.73 | ||
| ③ | 6,608,129,941 | 12,840,581,495 | 0.52 | 6,939,531,298 | 16,242,581,495 | 0.43 | 6,128,753,881 | 3,402,000,000 | 1.80 | ||
| 70% | 50% | ① | 6,993,758,039 | 12,840,581,495 | 0.55 | 7,197,118,469 | 13,089,991,495 | 0.55 | 6,009,641,804 | 249,410,000 | 24.10 |
| ② | 6,993,758,039 | 12,840,581,495 | 0.55 | 7,197,118,469 | 13,290,581,495 | 0.54 | 6,009,641,804 | 450,000,000 | 13.35 | ||
| ③ | 6,993,758,039 | 12,840,581,495 | 0.55 | 7,197,118,469 | 15,270,581,495 | 0.47 | 6,009,641,804 | 2,430,000,000 | 2.47 | ||
| 70% | ① | 6,993,758,039 | 12,840,581,495 | 0.55 | 7,263,990,817 | 13,189,755,495 | 0.55 | 6,128,753,881 | 349,174,000 | 17.55 | |
| ② | 6,993,758,039 | 12,840,581,495 | 0.55 | 7,266,990,817 | 13,470,581,495 | 0.54 | 6,128,753,881 | 630,000,000 | 9.73 | ||
| ③ | 6,993,758,039 | 12,840,581,495 | 0.55 | 7,266,990,817 | 16,242,581,495 | 0.45 | 6,128,753,881 | 3,402,000,000 | 1.80 | ||
Unit: KRW (average exchange rate in 2010 was 1 USD = 1,156.86 KRW). Estimated RDT kit demand based on suspected cases and tested cases using the RDT kit (Early diagnosis demand ①), estimating that the RDT kit demand will increase by 50% (Early diagnosis demand ②), estimating that 450 medical corps use RDT kits for febrile patients (Early diagnosis demand ③); the number is empirically estimated.
µ1 = use of chloroquine and primaquine during May and October, µ3 = early diagnosis of malaria with a RDT kit within 5 days of fever, B-C ratio = benefit-cost ratio, RDT = rapid diagnostic test.